{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:32:08Z","timestamp":1772001128555,"version":"3.50.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>\n                           <jats:italic toggle=\"yes\">MYC<\/jats:italic> translocation is a defining feature of Burkitt lymphoma (BL), and the new category of high-grade B-cell lymphomas with <jats:italic toggle=\"yes\">MYC<\/jats:italic> and <jats:italic toggle=\"yes\">BCL2<\/jats:italic> and\/or <jats:italic toggle=\"yes\">BCL6<\/jats:italic> translocations, and occurs in 6% to 15% of diffuse large B-cell lymphomas (DLBCLs). The low incidence of <jats:italic toggle=\"yes\">MYC<\/jats:italic> translocations in DLBCL makes the genetic study of all these lymphomas cumbersome. Strategies based on an initial immunophenotypic screening to select cases with a high probability of carrying the translocation may be useful. LMO2 is a germinal center marker expressed in most lymphomas originated in these cells. Mining gene expression profiling studies, we observed LMO2 downregulation in BL and large B-cell lymphoma (LBCL) with <jats:italic toggle=\"yes\">MYC<\/jats:italic> translocations, and postulated that LMO2 protein expression could assist to identify such cases. We analyzed LMO2 protein expression in 46 BLs and 284 LBCL. LMO2 was expressed in 1\/46 (2%) BL cases, 146\/268 (54.5%) DLBCL cases, and 2\/16 (12.5%) high-grade B-cell lymphoma cases with <jats:italic toggle=\"yes\">MYC<\/jats:italic> and <jats:italic toggle=\"yes\">BCL2<\/jats:italic> and\/or <jats:italic toggle=\"yes\">BCL6<\/jats:italic> translocations. All BLs carried <jats:italic toggle=\"yes\">MYC<\/jats:italic> translocation (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001), whereas LMO2 was only positive in 6\/42 (14%) LBCL with <jats:italic toggle=\"yes\">MYC<\/jats:italic> translocation (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001). The relationship between LMO2 negativity and <jats:italic toggle=\"yes\">MYC<\/jats:italic> translocation was further analyzed in different subsets of tumors according to CD10 expression and cell of origin. Lack of LMO2 expression was associated with the detection of <jats:italic toggle=\"yes\">MYC<\/jats:italic> translocations with high sensitivity (87%), specificity (87%), positive predictive value and negative predictive value (74% and 94%, respectively), and accuracy (87%) in CD10<jats:sup>+<\/jats:sup> LBCL. Comparing LMO2 and MYC protein expression, all statistic measures of performance of LMO2 surpassed MYC in CD10<jats:sup>+<\/jats:sup> LBCL. These findings suggest that LMO2 loss may be a good predictor for the presence of <jats:italic toggle=\"yes\">MYC<\/jats:italic> translocation in CD10<jats:sup>+<\/jats:sup> LBCL.<\/jats:p>","DOI":"10.1097\/pas.0000000000000839","type":"journal-article","created":{"date-parts":[[2017,3,11]],"date-time":"2017-03-11T15:53:21Z","timestamp":1489247601000},"page":"877-886","source":"Crossref","is-referenced-by-count":26,"title":["LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas"],"prefix":"10.1097","volume":"41","author":[{"given":"Luis","family":"Colomo","sequence":"first","affiliation":[{"name":"Department of Pathology, Hematopathology Unit, Hospital del Mar, Institute of Investigacions Mediques-IMIM, University Pompeu Fabra"},{"name":"Department of Pathology, Hematopathology Section, Hospital Clinic, Institute of Investigacions Biomediques Agust Pi Sunyer (IDIBAPS), University of Barcelona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivonne","family":"Vazquez","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Unit, Hospital del Mar, Institute of Investigacions Mediques-IMIM, University Pompeu Fabra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Papaleo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Unit, Hospital del Mar, Institute of Investigacions Mediques-IMIM, University Pompeu Fabra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Espinet","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Unit, Hospital del Mar, Institute of Investigacions Mediques-IMIM, University Pompeu Fabra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ferrer","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Unit, Hospital del Mar, Institute of Investigacions Mediques-IMIM, University Pompeu Fabra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catalina","family":"Franco","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Unit, Hospital del Mar, Institute of Investigacions Mediques-IMIM, University Pompeu Fabra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Comerma","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Unit, Hospital del Mar, Institute of Investigacions Mediques-IMIM, University Pompeu Fabra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Unit, Hospital del Mar, Institute of Investigacions Mediques-IMIM, University Pompeu Fabra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Calvo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Unit, Hospital del Mar, Institute of Investigacions Mediques-IMIM, University Pompeu Fabra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Salar","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Unit, Hospital del Mar, Institute of Investigacions Mediques-IMIM, University Pompeu Fabra"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fina","family":"Climent","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital de Bellvitge-IDIBELL, Hospitalet de Llobregat"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Mate","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Germans Trias i Pujol, Badalona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Forcada","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Mutua Terrassa, Terrassa, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mozos","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital de Sant Pau"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Nonell","sequence":"additional","affiliation":[{"name":"Microarray Analysis Service, Institute of Investigacions Mediques-IMIM, Barcelona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Section, Hospital Clinic, Institute of Investigacions Biomediques Agust Pi Sunyer (IDIBAPS), University of Barcelona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Carrio","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Section, Hospital Clinic, Institute of Investigacions Biomediques Agust Pi Sunyer (IDIBAPS), University of Barcelona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolors","family":"Costa","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Section, Hospital Clinic, Institute of Investigacions Biomediques Agust Pi Sunyer (IDIBAPS), University of Barcelona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Dlouhy","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Section, Hospital Clinic, Institute of Investigacions Biomediques Agust Pi Sunyer (IDIBAPS), University of Barcelona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itziar","family":"Salaverria","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Section, Hospital Clinic, Institute of Investigacions Biomediques Agust Pi Sunyer (IDIBAPS), University of Barcelona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Ignacio","family":"Martin-Subero","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Section, Hospital Clinic, Institute of Investigacions Biomediques Agust Pi Sunyer (IDIBAPS), University of Barcelona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Lopez-Guillermo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Section, Hospital Clinic, Institute of Investigacions Biomediques Agust Pi Sunyer (IDIBAPS), University of Barcelona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Valera","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Section, Hospital Clinic, Institute of Investigacions Biomediques Agust Pi Sunyer (IDIBAPS), University of Barcelona"},{"name":"Institute of Pathology, Locarno, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Campo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Section, Hospital Clinic, Institute of Investigacions Biomediques Agust Pi Sunyer (IDIBAPS), University of Barcelona"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J Clin Oncol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3324\/haematol.2013.086173","article-title":"MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"98","author":"Valera","year":"2013","journal-title":"Haematologica"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1182\/blood-2013-05-498329","article-title":"Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification","volume":"122","author":"Ott","year":"2013","journal-title":"Blood"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/modpathol.2013.214","article-title":"Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP","volume":"27","author":"Tzankov","year":"2014","journal-title":"Mod Pathol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"20","author":"Barrans","year":"2010","journal-title":"J Clin Oncol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3109\/10428194.2012.731598","article-title":"Genomic arrays in chronic lymphocytic leukemia routine clinical practice: are we ready to substitute conventional cytogenetics and fluorescence in situ hybridization techniques? Leuk","volume":"54","author":"Puiggros","year":"2013","journal-title":"Lymphoma"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/asheducation-2014.1.90","article-title":"Diagnosis of \u201cdouble hit\u201d diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC","volume":"2014","author":"Swerdlow","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A biologic definition of Burkitt\u2019s lymphoma from transcriptional and genomic profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"N Engl J Med"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt\u2019s lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/jcp.2008.057257","article-title":"Retracted: immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)","volume":"62","author":"de Jong","year":"2008","journal-title":"J Clin Pathol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1182\/blood-2006-08-039024","article-title":"The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas","volume":"109","author":"Natkunam","year":"2007","journal-title":"Blood"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2353\/jmoldx.2006.050083","article-title":"FISH Analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue","volume":"8","author":"Ventura","year":"2006","journal-title":"J Mol Diagn"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/PAS.0b013e3181f3e29f","article-title":"IG\/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas","volume":"34","author":"Valera","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1525-1497.2002.10750.x","article-title":"Simplifying likelihood ratios","volume":"17","author":"McGee","year":"2002","journal-title":"J Gen Intern Med"},{"key":"R26-20230922","first-page":"1","article-title":"rpart: Recursive Partitioning. Rpart Packag. manual","volume":"4","author":"Therneau","year":"2015","journal-title":"R Packag"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2559.2012.04198.x","article-title":"Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody","volume":"61","author":"Agostinelli","year":"2012","journal-title":"Histopathology"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/PAI.0000000000000107","article-title":"Diagnostic utility of the germinal center\u2013associated markers GCET1, HGAL, and LMO2 in hematolymphoid neoplasms","volume":"23","author":"Menter","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma","volume":"100","author":"Wright","year":"2003","journal-title":"Proc Natl Acad Sci US"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1200\/JCO.2007.13.0690","article-title":"LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab","volume":"26","author":"Natkunam","year":"2008","journal-title":"J Clin Oncol"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","article-title":"MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study","volume":"126","author":"Copie-Bergman","year":"2015","journal-title":"Blood"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/modpathol.2016.71","article-title":"Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression","volume":"29","author":"Valera","year":"2016","journal-title":"Mod Pathol"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/his.12178","article-title":"MYC status determination in aggressive B-cell lymphoma: the impact of FISH probe selection","volume":"63","author":"Mu\u00f1oz-M\u00e1rmol","year":"2013","journal-title":"Histopathology"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1182\/blood-2012-01-403154","article-title":"Identification of LMO2 transcriptome and interactome in diffuse large B-cell,lymphoma","volume":"119","author":"Cubedo","year":"2012","journal-title":"Blood"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1126\/science.1987636","article-title":"Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region","volume":"251","author":"Prendergast","year":"1991","journal-title":"Science"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"e26837","DOI":"10.1371\/journal.pone.0026837","article-title":"Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma","volume":"6","author":"Seitz","year":"2011","journal-title":"PLoS One"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201707000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:18:33Z","timestamp":1695421113000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201707000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000000839","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}